October 2017 Liquid Biopsy News Highlights
;tldr: Subscribe to our weekly liquid biopsy-related news highlights, here
ANGLE to Offer a Full Liquid Biopsy ‘Sample to Answer’ Solution Following Axela Acquisition
Proactive Investors – Oct. 5, 2017
The Axela system will complement Parsortix by providing an analysis element to ANGLE’s offering, enabling the UK company to capture a greater proportion of the liquid biopsy value chain.
Tempus Unveils Tempus xT, 595 Gene Panel Aimed at Empowering Data-Driven Cancer Care
Nasdaq GlobeNewswire – Oct. 19, 2017
Tempus announced the launch of its new comprehensive genomic sequencing panel, Tempus xT, which sequences a patient’s tumor DNA and RNA to help the clinicians determine the targeted therapies and/or clinical trials that are most appropriate for their patients.
Admera Health Launches New Tests for Cancer Supportive Care and Liquid Biopsy, Now Provides a Comprehensive Portfolio of Oncology Products
Nasdaq – Oct. 31, 2017
Admera Health announced the launch of multiple lab oratory developed tests: PGxOnco(TM), for cancer supportive care, and LiquidGx(TM), a suite of liquid biopsy based tests for tumor profiling and drug resistance monitoring.
Precipio Receives First Ice Cold-Pcr(TM) Kit Order from Clearbridge Health
Baystreet – Oct. 31, 2017
Precipio, Inc. announced that Clearbridge Health, Pte. Ltd. (CBH), a Singapore-based healthcare company, intends to launch Precipio’s RUO ICE COLD-PCR™ (ICP) Liquid Biopsy technology.
Regulatory and Reimbursement Updates
Foundation Medicine Receives Approval from the State of New York for its FoundationACT Liquid Biopsy Assay
Company Press Release – Oct. 2, 2017
Foundation Medicine, Inc. announced that it received approval from the New York State Clinical Laboratory Evalution Program (CLEP) for its FoundationACT® blood-based circulating tumor DNA (ctDNA) assay.
Thermo Fisher Scientific’s Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from Regional Health Plan
PR Newswire – Oct. 16, 2017
Thermo Fisher Scientific announced its Oncomine Dx Target Test has received a positive coverage decision by Regence BlueCross/BlueShield. The declaration makes the next-generation sequencing (NGS)-based companion diagnostic for non-small cell lung cancer (NSCLC) available to members in four states.
The FDA Has Approved a Faster Way to Check for Allergies
Futurism – Oct. 23, 2017
The U.S. FDA just approved a diagnostic method that uses just a drop of blood to find out if you have one of the four most common allergies, and it only takes 8 minutes top.
Key Partnerships and Collaborations
Biocept and Miraca Life Sciences Enter into Marketing Agreement to Expand Target Selector Testing in the United States
PR Newswire – Oct. 3, 2017
Biocept announced its Promotion and Marketing Agreement with Miraca Life Sciences, Inc. (MLS) to market Biocept’s Target Selector™ liquid biopsy tests and services to community-based oncologists and hematologists in specified sales territories in the United States.
HORIBA Medical and Siemens Healthineers Enter into Agreement to Expand Laboratory Hematology Offerings
Company Press Release – Oct. 9, 2017
HORIBA Medical announced that it has entered into a long term agreement with Siemens Healthineers. The agreement will combine the complimentary innovative technology offerings of each company to address the multidisciplinary requirements of IVD testing customers.
Thermo Fisher, Inivata, Genomics England to Assess Liquid Biopsy for Cancer Patient Management
Genome Web – Oct. 13, 2017
Genomics England announced its collaboration with Inivata and Thermo Fisher Scientific to assess the potential of liquid biopsy to improve disease management and outcomes for cancer patients.
Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals
PR Newswire – Oct. 18, 2017
Biocept announced the launch of its molecular pathology partnership initiative, the aim of which is to incorporate community pathologists into the review of biomarkers found in liquid biopsy for patients diagnosed with cancer.
NanoString and the NSABP Foundation Enter into Agreement to Study Immunophenotypes in Colorectal Cancer
Company Press Release – Oct. 26, 2017
Collaboration will use PanCancer IO360 assay which incorporates the tumor inflammation signature (TIS) and mismatch repair genes (MMR) for assessment of MSI-H phenotype.
OncoDNA Inks Latvian Distribution Deal With CyberKnife Sigulda
Genome Web – Oct. 30, 2017
OncoDNA said today that CyberKnife Sigulda will market and distribute its tumor profiling solutions for clinical use in Latvia.
MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDs for Prostate Cancer
Nasdaq NewsFeed – Oct. 30, 2017
MDxHealth agency service agreement for SelectMDx with Swiss-based Unilabs, one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services.
ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield Vermillion
Pharmiweb – Oct. 31, 2017
ASPiRA Labs, a Vermillion company and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with Blue Cross Blue Shield of Louisiana.
Thermo Fisher Scientific, Blueprint Medicines Ink Companion Diagnostic Development Deal
Genome Web – Oct. 31, 2017
Thermo Fisher Scientific said today that it has partnered with Blueprint Medicines to develop and commercialize its Oncomine Dx Target Test as a companion diagnostic for Blueprint’s BLU-667 to identify RET fusions in non-small cell lung cancer patients.
Belgian Biotech Gathers Major Oncology Centers to Tackle Cancer with Big Data
LABIOTECH.eu – Oct. 18, 2017
The Belgian biotech OncoDNA has announced that it will be collaborating with the Strasbourg University Hospital, France and the Oncology Center of Bydgoszcz, Poland, in the advancement of precision medicine for cancer.
Research and Clinical Validation Updates
Intermountain Healthcare Researchers Launch Major Three-Year Genomics Breast Cancer Study
Company Press Release – Oct. 8, 2017
Cancer researchers at Intermountain Medical Center and the Intermountain Precision Genomics Program are launching a study to determine if a blood test that looks for DNA from a cancer tumor can be used to complement mammography to improve the way breast cancer is diagnosed.
Angle’s Parsortix(TM) System Showcased in Multiple Presentations at Leading European Circulating Tumour Cell Conference
Market Wired – Oct. 9, 2017
ANGLE announced that its Parsortix™ system was widely showcased by the Company’s customers and Key Opinion Leaders in the field of circulating tumour cells (CTCs) in presentations at Europe’s leading CTC conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium, which recently took place in Rhodes, Greece, 4 to 7 October 2017.
Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017
Nasdaq GlobeNewswire – Oct. 17, 2017
Inivata announced that new clinical data from its collaboration with DanaFarber Cancer Institute will be presented at the World Conference on Lung Cancer (WCLC). The study involved a blind retrospective evaluation of Inivata’s InVision ctDNA liquid biopsy analysis to characterize and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib.
NSCLC: Liquid Biopsy May Predict Patient Response to Immune Checkpoint Inhibition
Lung Cancer Advisor – Oct. 25, 2017
PD-L1 status in circulating tumor cells (CTCs) and white blood cells (WBCs) correlates with PD-L1 status in non-small cell lung cancer (NSCLC) tissues, according to recently published research.
BioSequence Commences Clinical Trial of OncoDNA’s Cancer of Unknown Primary Test
Genomeweb – Oct. 16, 2017
BioSequence has embarked on a year-long study of OncoDNA’s OncoDeep CUP service in Spain, looking to raise the profile of the genomic offering among clinicians, and to strengthen its case for reimbursement.
Quest Diagnostics Acquires California Laboratory Associates
PR Newswire – Oct. 30, 2017
Quest announced that it has acquired certain assets of California Laboratory Associates (CLA), a clinical lab network serving patients and providers in the Greater Los Angeles Area.
Avalon GloboCare Acquires Leading Beijing Exosome Technology Company
Markets Insider – Oct. 30, 2017
Avalon GloboCare Corp. announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng Biotech Co. Ltd. Beijing GenExosome’s research systems are designed to be used by researchers for biomarker discovery and clinical diagnostic development, and the advancement of targeted therapies.
Anpac Bio Surpasses 50,000 Case Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers
Markets Insider – Oct. 18, 2017
Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company’s proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy tests.
New Patent Issued to Nanomedical Diagnostics for Use of Graphene Biosensors with DNA Probes to Identify DNA Sequences for Precision Medicine
PRweb – Oct. 18, 2017
Nanomedical Diagnostics announced the grant of U.S. Patent by the United States Patent and Trademark Office. The patent covers use of graphene biosensors with DNA probes to nucleic acids, and it builds on a previous comprehensive patent for monitoring biomolecular interactions on which the company’s flagship product, the Agile R100 personal assay system, is based.
ANGLE PLC’s Parsortix Liquid Biopsy Top in Kidney Cancer Study
Proactive Investers UK – Oct. 18, 2017
ANGLE PLC’s Parsortix system has outperformed comparable liquid biopsies in a new study undertaken on kidney cancer sufferers in Germany.
VisionGate Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
Nasdaq GlobeNewswire – Oct. 19, 2017
VisionGate, Inc. reported significant findings in three recent studies at the 18th annual World Conference of Lung Cancer (IASLC). These studies demonstrate important applications of the LuCED Lung Test for detection and treatment of lung cancer and pre-cancerous bronchial dysplasia.
Want more news? Subscribe to our weekly liquid biopsy-related news highlights, here
Get the rest of the data, including details on research, funding, and product activity through our Liquid Biopsy CI Tool